Patient characteristics (n = 25)
| Characteristic | Value |
|---|---|
| Age, years, mean (SD) | 60 (11) |
| Male, n (%) | 15 (60) |
| Race/ethnicity, n (%) | |
| White | 16 (64) |
| Hispanic | 5 (20) |
| Other | 4 (16) |
| Ever smoker, n (%) | 12 (48) |
| Comorbidities, n (%) | |
| Diabetes mellitus type 2 | 6 (24) |
| Hypertension | 18 (72) |
| Hyperlipidemia | 11 (44) |
| Ischemic heart disease | 5 (20) |
| Body mass index, kg/mm2, mean (SD) | 28 (5) |
| Cancer type, n (%) | |
| Genitourinary cancer | 9 (36) |
| Hematologic cancer | 5 (20) |
| Melanoma | 4 (16) |
| Gastrointestinal cancer | 4 (16) |
| Other | 3 (12) |
| Cancer stage, n (%)a | |
| III | 4 (16) |
| IV | 16 (64) |
| ICI type, n (%) | |
| Anti–CTLA-4 | 8 (32) |
| Anti–PD-1/L1 | 15 (60) |
| Combination | 2 (8) |
| ICI given with chemotherapy known to cause gallbladder disease, n (%) | 4 (16) |
| Other irAEs, n (%) | |
| Skin | 4 (16) |
| Lungs | 3 (12) |
| Endocrine | 3 (12) |
| Colitis | 1 (4) |
| Hepatitis | 1 (4) |
| Other | 2 (8) |
aAvailable for 20 patients with solid tumors. SD standard deviation, ICI immune checkpoint inhibitor, CTLA-4 cytotoxic T-lymphocyte associated antigen 4, PD-1/L1 programmed cell death protein 1 or its ligand, irAE immune-related adverse event